Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia

Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Administration approved for relapsed or refractory B-AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Moskop, Amy, Pommert, Lauren, Baggott, Christina, Prabhu, Snehit, Pacenta, Holly L., Phillips, Christine L., Rossoff, Jenna, Stefanski, Heather E., Talano, Julie-An, Margossian, Steve P., Verneris, Michael R., Myers, G. Doug, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle L., Satwani, Prakash, Krupski, Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Fabrizio, Vanessa A., Chinnabhandar, Vasant, Goksenin, A. Yasemin, Curran, Kevin J., Mackall, Crystal L., Laetsch, Theodore W., Guest, Erin M., Breese, Erin H., Schultz, Liora M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327536/
https://www.ncbi.nlm.nih.gov/pubmed/35580324
http://dx.doi.org/10.1182/bloodadvances.2021006393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327536/
https://www.ncbi.nlm.nih.gov/pubmed/35580324
http://dx.doi.org/10.1182/bloodadvances.2021006393

Ejemplares similares